Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Kalaris Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:KLRS | Benzinga

Q: What sector and industry does Kalaris Therapeutics (KLRS) operate in?

Kalaris Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Explore Kalaris Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KLRS.

Open	$7.14
Close	$6.88
Volume / Avg.	146.02K / 39.91K
Day Range	$6.58 - $8.31
52 Wk Range	5.87 - 12.90
Market Cap	$127.18M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	19
Short Interest	-
Days to Cover	2.16

Recent News

No news found

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Apr

Buy

Hold

Sell

Strong Sell

Open	$7.14
Close	$6.88
Volume / Avg.	146.02K / 39.91K
Day Range	$6.58 - $8.31
52 Wk Range	5.87 - 12.90
Market Cap	$127.18M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	19
Short Interest	-
Days to Cover	2.16

About Kalaris Therapeutics Inc.

Sector

Health Care

Industry

Biotechnology

Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and com...

Got Questions? Ask

Analyze KLRS's financials

Analyze KLRS's market performance

How is KLRS's EV/EBITDA ratio?

How is KLRS's revenue growing?

Show KLRS's technical analysis

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Kalaris Therapeutics (KLRS) stock?

You can purchase shares of Kalaris Therapeutics (NASDAQ:KLRS) through any online brokerage.

View our list of the best stock brokerages

Who are Kalaris Therapeutics (KLRS) competitors?

Other companies in Kalaris Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), 4D Molecular Therapeutics (NASDAQ:FDMT), Korro Bio (NASDAQ:KRRO) and Larimar Therapeutics (NASDAQ:LRMR).

What is the forecast, or price target, for Kalaris Therapeutics (KLRS) stock?

There is no analysis for Kalaris Therapeutics to provide a consensus price target.

What is the current price for Kalaris Therapeutics (KLRS)?

The stock price for Kalaris Therapeutics (NASDAQ: KLRS) is $6.8 last updated April 11, 2025 at 6:33 AM EDT.

Does Kalaris Therapeutics (KLRS) pay a dividend?

There are no upcoming dividends for Kalaris Therapeutics.

When is Kalaris Therapeutics (NASDAQ:KLRS) reporting earnings?

Kalaris Therapeutics’s Q1 earnings are confirmed for Thursday, May 15, 2025.

Is Kalaris Therapeutics (KLRS) going to split?

There is no upcoming split for Kalaris Therapeutics.

What sector and industry does Kalaris Therapeutics (KLRS) operate in?

Kalaris Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Kalaris Therapeutics Stock Price, Quotes and Forecasts

Kalaris Therapeutics (KLRS) Forecast